Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05608044 |
TitleA Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer Without Liver Metastases | Phase
Phase 2
|
Date Added 2022-11-08 |
Location
Arizona, United States
California, United States Colorado, United States Delaware, United States Florida, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Rhode Island, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Belgium Brazil France Georgia Italy Russian Federation Spain |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Balstilimab, Botensilimab, Regorafenib, TAS-102 |
Tags
MSS/ MMRp
|
| NCT ID NCT04895709 |
TitleA Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors | Phase
Phase 1, Phase 2
|
Date Added 2021-05-20 |
Location
California, United States
Iowa, United States New Jersey, United States New York, United States Oregon, United States Tennessee, United States Texas, United States Australia Canada Germany Israel Italy Japan Spain |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
BMS-936558-01, BMS-986340 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03400332 |
TitleA Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers | Phase
Phase 2
|
Date Added 2018-01-17 |
Location
Arkansas, United States
California, United States Colorado, United States Georgia, United States Maryland, United States Massachusetts, United States Michigan, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Texas, United States Utah, United States Virginia, United States Australia Belgium Canada France Germany Italy Poland Spain Sweden Switzerland United Kingdom |
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
BMS-986253, Ipilimumab, Nivolumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03289962 |
TitleA Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | Phase
Phase 1
|
Date Added 2017-09-21 |
Location
Arizona, United States
California, United States Colorado, United States Connecticut, United States Massachusetts, United States Nevada, United States New York, United States Oklahoma, United States Oregon, United States Tennessee, United States Washington, United States Belgium Canada Germany Netherlands Spain Sweden United Kingdom |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Atezolizumab, Autogene cevumeran, Tecentriq |
Tags
MSS/ MMRp
|
| NCT ID NCT05684211 |
TitleA Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer | Phase
Phase 2
|
Date Added 2023-01-13 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs
Ametumumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05167409 |
TitleA Study of ALX148 With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2021-12-22 |
Location
Arizona, United States
Colorado, United States New Jersey, United States Virginia, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
ALX148, cetuximab, Evorpacept (ALX148), Pembrolizumab, Erbitux, Keytruda |
Tags
MSS/ MMRp
|
| NCT ID NCT05382442 |
TitleA Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2022-05-19 |
Location
California, United States
China |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
5-Fluorouracil, Bevacizumab, capecitabine, Irinotecan, Leucovorin, oxaliplatin |
Tags
MSS/ MMRp
|
| NCT ID NCT02988960 |
TitleA Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors | Phase
Phase 1
|
Date Added 2016-12-12 |
Location
California, United States
Illinois, United States Massachusetts, United States North Carolina, United States Tennessee, United States Texas, United States Virginia, United States Australia Canada France Japan Korea, Republic of Spain |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
ABBV-181, ABBV-927, Opdivo |
Tags
MSS/ MMRp
|
| NCT ID NCT05141721 |
TitleA Study of a Personalized Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2021-12-02 |
Location
Arizona, United States
Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Maryland, United States Michigan, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Wisconsin, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Atezolizumab, Bevacizumab, Fluoropyrimidine, GRT-C901, GRT-R902, Ipilimumab, oxaliplatin |
Tags
MSS/ MMRp
|
| NCT ID VAPER |
TitleA study looking at using a vaccine and chemotherapy to treat advanced cancer | Phase
Phase 1
|
Date Added 2015-11-17 |
Location |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Celecoxib, Cyclophosphamide, imiquimod, vaccine |
Tags
MSS/ MMRp
|
